Pharmaceuticals company Zydus Lifesciences announced Q1FY26 results Revenue from Operations was Rs 65,737 million, up 6% YoY. Research & Development (R&D;) investments for the quarter stood at Rs 4,856 million (7.4% of revenue). EBITDA for the quarter was Rs 20,885 million, flat YoY. EBITDA margin for the quarter stood at 31.8%. Net Profit for the quarter was Rs 14,668 million, up 3% YoY. Capex (organic) for the quarter was Rs 4,020 million. Sharvil Patel, Managing Director, Zydus Lifesciences, said, "Our Q1FY26 performance reflects the results of our disciplined execution, with most of our key businesses meeting expectations. We remain firmly on track to achieve our FY26 aspirations and are excited about the upcoming developments on the innovation front, which we believe will open up new avenues for sustainable growth. As we pursue these opportunities, we continue to keep the highest standards of compliance at the core of all our operations, while building strong future growth pillars that will strengthen our position globally". Result PDF